Form 4: CervoMed Director Joshua Boger Receives Stock Option Grant

Director Joshua Boger was granted options to purchase 8,150 shares of CervoMed common stock following his election to the board.

Summary

• Joshua Boger, a director and 10% owner of CervoMed Inc., received a grant of 8,150 stock options.
• The grant was issued on June 8, 2026, in connection with his election to the board of directors at the 2026 Annual Meeting of Stockholders.
• The options have an exercise price of $2.91 per share.
• The options vest in 1/12th increments monthly over a one-year period, starting June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation practice consistent with the company's 2025 Equity Incentive Plan.

Negatives

• Minor dilution potential for existing shareholders upon future exercise of options.

Risks

• Market price volatility could impact the value of the granted options.
• Vesting is contingent upon continued service as a director.

Future Outlook

The options vest monthly over one year, contingent on the director's continued service to the company.

Management Comments

• The grant is in accordance with the terms of the Issuer's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that standard equity grants for board members are common practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotech firms.
• The use of a 12-month vesting period is a standard retention mechanism for board members.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the grant relative to total outstanding shares.

Next Steps

• Monthly vesting of options beginning June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Insider Trading, Stock Options, Director Compensation